Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ALXO with free AI briefings, catalyst countdowns, and dilution alerts.

ALXO · ALX Oncology Holdings Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$147.2M Cash on Hand
28.7mo Cash Runway
5% Short Interest
$4.6 Analyst Target (5)
Follow ALXO by email Get an email when ALXO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALXO, unsubscribe in one click. Privacy

📣 What ALXO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Evorpacept (ALX148) Gastric Cancer Phase 2/3 · NCT05002127 Completed
MicroRNA-10b Antagomir-Iron Oxide/Dextran-based… HER2-positive Breast Cancer Phase 1/2 · NCT05868226 Recruiting
Eribulin Breast Cancer, Metastatic Phase 2 · NCT07007559 Recruiting
Doxorubicin Ovarian Cancer Phase 2 · NCT05467670 Active not recruiting
Fluorouracil Metastatic Cancer Phase 1 · NCT03013218 Completed
Anti-EGFR/Top1i ADC ALX2004 NSCLC (Advanced Non-small Cell Lung Cancer) Phase 1 · NCT07085091 Recruiting

Also used in these trials (approved or third-party drugs, not ALXO's own candidates): Trastuzumab, Ramucirumab, Paclitaxel, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Vinorelbine, Tucatinib, Pembrolizumab, Gemcitabine Hydrochloride, Cisplatin, Cetuximab, Capecitabine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALXO holds $147.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.4M/quarter from operations, an estimated runway of 28.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALXO files for a raise →

👥 Who Owns ALXO

Insiders 10.4% Other 5%+ holders 6.6% Institutions (139 holders) 83% Public and other holders 0%
HolderTypeShares% of sharesAs of
RA Capital Management, L.P. Institution (13G, 5%+) 13,117,106 10.15% 2026-02-02
Corey S Goodman
Director, 10% owner · +40,400 options
Insider 12,927,442 10.00% 2026-10-14
venBio Partners LLC Institution (13F) 12,884,638 9.97% 2026-09-30
HBM Healthcare Investments (Cayman) Ltd. 5%+ holder (13G) 8,590,692 6.65% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 7,327,850 5.67% 2026-06-30
Redmile Group, LLC Institution (13F) 7,185,263 5.56% 2026-09-30
Blackstone Inc Institution (13F) 6,775,543 5.24% 2026-09-30
SilverArc Capital Management, LLC Institution (13F) 6,565,960 5.08% 2026-09-30
Driehaus Capital Management, LLC Institution (13F) 6,025,240 4.66% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 4,748,830 3.67% 2026-09-30
Marshall Wace LLP Institution (13F) 3,148,217 2.44% 2026-09-30
5AM Venture Management, LLC Institution (13F) 3,057,325 2.36% 2026-09-30

Share count 129,274,568 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-17
filed 2026-08-18
Lettmann Jason
Sale (S) 2,230 $1.93 294,379
2026-08-17
filed 2026-08-18
Wong Shelly
Sale (S) 573 $1.93 87,828
2026-07-01
filed 2026-07-06
Wong Shelly
Sale (S) 1,404 $2.04 88,401
2026-04-16
filed 2026-04-17
Knight Jeff E.
Option award (A) 800,000 – –
2026-04-16
filed 2026-04-17
Klencke Barbara
Option award (A) 100,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ALXO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALXO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.